Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 27, 2026

Barclays (LSE:BARC) Valuation Check After Recent Share Price Weakness And Mixed Return Profile

View original at finance.yahoo.com
Barclays (LSE:BARC) Valuation Check After Recent Share Price Weakness And Mixed Return Profile Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The most followed view sees Barclays as 27.2% undervalued with a fair value of £5.30 versus current price of £3.8545

    60% confidence

  • Predictable, multi-year structural hedge income and net interest income momentum, supported by disciplined deposit management, asset repricing and loan growth, will underpin consistent NII growth and support progressive shareholder distributions, enhancing earnings visibility

    60% confidence

  • Tougher competition for UK deposits, or setbacks integrating acquisitions like Tesco Bank or a potential Evelyn Partners deal, could quickly challenge the upbeat valuation view

    60% confidence

  • Barclays is trading at an intrinsic discount of about 58% with a value score of 6

    60% confidence

Data points we hold from this source

Barclays · one year total shareholder return30 percent
Barclays · thirty day return-16 percent
Barclays · three month return-18 percent
Barclays · value score6 score
Barclays · year to date return-20 percent
Barclays · fair value5.30 GBP
Barclays · five year total shareholder return150 percent
Barclays · intrinsic discount58 percent
Barclays · one month return-16 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Barclays (LSE:BARC) Valuation Check After Recent Share Price Weakness And Mixed Return Profile — Source | Via News | ViaNews EU